This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Kulcsar, University Hospital Zurich milla1cf Mon, 02/26/2024 - 12:13 February 26, 2024 — Ischemic strokes are a major health burden. Many stroke patients recover poorly despite timely treatment To treat these symptoms and restore blood flow to the brain, the obstructed vessel needs to be “declogged”, or recanalized.
Stroke, Ahead of Print. After 30 years of disappointment, 2 randomized controlled trials investigating the effect of neurosurgical treatment on functional outcome in patients with intracerebral hemorrhage were published in 2024.
UVA Health's Karen Johnston, MD, the SHINE trial leader, was pleased to see the new insights into best practices for stroke care. These data from the SHINE trial continue to inform the national stroke community about potential approaches to treating hyperglycemic stroke patients to assure better outcomes,” she said.
Findings from the highly-anticipated MOST (Multi-Arm Optimization of Stroke Thrombolysis) trial were presented on the first day of the American Stroke Association’s International Stroke Conference, ISC 2024, being held through Feb. The study was looking for improvement in functional outcomes at 90 days. 9 Phoenix, AZ.
Image courtesy: Getty Images christine.book Thu, 02/08/2024 - 15:53 February 8, 2024 — The latest late-breaking science from the second day of the American Stroke Association ’s International Stroke Conference , ISC 2024 , shed light on the use of artificial intelligence ( AI ) to help guide treatment decisions for stroke patients.
Stroke, Volume 56, Issue 2 , Page 285-293, February 1, 2025. BACKGROUND:Sex-specific differences in stroke risk factors, clinical presentation, and outcomes are well documented. Primary end points were 90-day readmission for ischemic stroke or hemorrhage and compared between men and women.
Stroke, Volume 56, Issue Suppl_1 , Page A125-A125, February 1, 2025. Introduction:Managing post-acute hemorrhagicstroke care is complex and necessitates close follow-up and coordination. Ninety-day modified Rankin Scale (mRS) evaluated functional outcomes analyzed using a proportional odds logistic regression.
announced the primary endpoint results of its EvaQ Trial , a prospective, multi-center, global, single arm, FDA-regulated IDE trial study to evaluate the safety and effectiveness of the MIVI Q Revascularization System for treating acute ischemic stroke. milla1cf Fri, 02/09/2024 - 09:28 February 9, 2024 — MIVI Neuroscience, Inc. mTICI 2b/3.
Stroke, Volume 56, Issue Suppl_1 , Page ADP8-ADP8, February 1, 2025. the 2023 calendar year, our comprehensive stroke metric for hemorrhagicstroke scoring was at 64%, below the 'Get with the Guidelines' benchmark of 87%.To We continue to assess compliance and project feasibility.We
Stroke, Volume 56, Issue Suppl_1 , Page ATP199-ATP199, February 1, 2025. Introduction:Intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH) are severe forms of stroke with high morbidity and mortality rates. These findings highlight the potential neuroprotective role of statins in hemorrhagicstroke.
Stroke, Volume 56, Issue Suppl_1 , Page AWP230-AWP230, February 1, 2025. Hemorrhagicstrokes (HS) are increasingly significant causes of disability and mortality worldwide, making the use of blood biomarkers for their diagnosis and prognosis critical. Survivors had GFAP levels of 1.35
Stroke, Volume 56, Issue Suppl_1 , Page AWP236-AWP236, February 1, 2025. Background:A novel inflammatory score has been validated for hematoma expansion and poor outcomes in patients with intracerebral hemorrhage. Inflammatory score was significantly higher in patients with hemorrhagic transformation.
Stroke, Volume 56, Issue Suppl_1 , Page ATP170-ATP170, February 1, 2025. In stroke, it has been associated with infarct growth, hemorrhagic transformation, and poor outcomes. WMD burden was assessed using Fazekas scoring on post-stroke T2 FLAIR sequences by three raters.
Stroke, Volume 55, Issue Suppl_1 , Page AWP164-AWP164, February 1, 2024. Introduction:Patients who have had hemorrhagicstrokes experience psychological and functional deficits after hospital discharge. Social Determinants of Health (SDoH) can also impact outcomes.
BackgroundIntravenous thrombolysis (IVT) is an effective stroke therapy that remains underused. In this study we aim to investigate the safety and efficacy of IVT in patients with acute ischemic stroke and recent DOAC use.Methods and ResultsA systematic review and meta‐analysis of proportions evaluating IVT with recent DOAC use was conducted.
Stroke, Volume 56, Issue Suppl_1 , Page ATMP18-ATMP18, February 1, 2025. Background and Issues:Timely identification and intervention are critical for positive outcomes in acute intracerebral hemorrhage (ICH) patients. Conclusions:Having measurable goals for ICH has demonstrated a significant improvement in outcomes.
Stroke, Volume 55, Issue 1 , Page 50-58, January 1, 2024. BACKGROUND:The effect of marine omega-3 PUFAs on risk of stroke remains unclear.METHODS:We investigated the associations between circulating and tissue omega-3 PUFA levels and incident stroke (total, ischemic, and hemorrhagic) in 29 international prospective cohorts.
Stroke, Volume 56, Issue Suppl_1 , Page ATP190-ATP190, February 1, 2025. Background:The prognostic significance of the affected hemisphere in hemorrhagicstroke remains uncertain. The association of ICH laterality with clinical outcomes was estimated using multiple linear regression models.
Stroke, Volume 56, Issue Suppl_1 , Page AWMP80-AWMP80, February 1, 2025. Introduction:Stroke is a devastating complication of infective endocarditis (IE) and is associated with poor outcomes. Out of 526 cases, 511 had active infection and were screened for acute stroke associated with IE.
Stroke, Volume 56, Issue Suppl_1 , Page AWP155-AWP155, February 1, 2025. Background:Cancer-related stroke (CRS) is a rare condition where a tumor or its metastasis can compress a blood vessel and result in stroke. Patients were divided into those with strokes (ischemic or hemorrhagic) and those without strokes.
Stroke, Volume 56, Issue Suppl_1 , Page AWP228-AWP228, February 1, 2025. Introduction:Intracerebral hemorrhage (ICH) volume and expansion are important predictors of clinical outcome. Recent results show volumetric thresholds for prediction of poor outcome differ based on the anatomic location (lobar vs deep) of the ICH.
Stroke, Volume 56, Issue Suppl_1 , Page ATP205-ATP205, February 1, 2025. Introduction:Alzheimers Disease (AD), characterized by extracellular deposition of amyloid beta (A) plaques in brain tissue, is often comorbid with cerebral amyloid angiopathy, which carries an elevated risk of intracranial hemorrhage. andICD-10-CMcode G30.x.
Stroke, Volume 56, Issue Suppl_1 , Page AWMP79-AWMP79, February 1, 2025. Background and Purpose:The inflammatory response after ischemic and hemorrhagicstroke is associated with worse clinical outcomes through immune mediated production of pro- inflammatory cytokines.
Stroke, Ahead of Print. The primary outcome was functional status measured by the modified Rankin Scale at 90 to 180 days. Earlier SBP control was associated with better functional outcomes (modified Rankin Scale score, 3–6; odds ratio, 0.98 [95% CI, 0.97–0.99]) SD, 13.0], 2120 [36.8%] females) were included in analyses.
We aimed to investigate the prevalence and prognostic implications of AMI in primary intracerebral hemorrhage.Methods and ResultsWe retrospectively analyzed patients with primary intracerebral hemorrhage within 48 hours after symptom onset. Patients were followed for up to 5 years. Of 600 patients included, 115 had AMI (19.2%).
Stroke, Volume 56, Issue Suppl_1 , Page ATP343-ATP343, February 1, 2025. Background:Subarachnoid Hemorrhage (SAH) accounts for 2-7% of strokes and has high mortality and morbidity. The identified genes and networks may guide the search for potential biomarkers of outcome and novel treatment targets.
Stroke, Volume 56, Issue Suppl_1 , Page AWP51-AWP51, February 1, 2025. The exposure was an incident diagnosis of non-traumatic intracranial hemorrhage, defined as a composite of intracerebral hemorrhage, subarachnoid hemorrhage, or subdural hemorrhage. The outcome was an incident diagnosis of dementia.
Stroke, Volume 55, Issue Suppl_1 , Page ATMP81-ATMP81, February 1, 2024. Background and Purpose:Post thrombolytic intracerebral hemorrhage (ICH) is associated with higher rate of death or disability in acute ischemic stroke patients. Outcomes were determined by using utility weighted modified Rankin scale (UW-mRs) at 90-days.
Stroke, Volume 56, Issue Suppl_1 , Page AWP82-AWP82, February 1, 2025. Background:ICH accounts for 10% of all strokes and is deadliest and most disabling stroke subtype. Patients with anticoagulant-related hemorrhage require rapid reversal to mitigate risk of hematoma expansion.
Stroke, Volume 56, Issue Suppl_1 , Page A85-A85, February 1, 2025. Background:Systolic blood pressure (SBP) fluctuation is linked to increased death or disability in intracerebral hemorrhage (ICH) patients. These findings suggest this time window is crucial for future interventions aimed at controlling SBP in ICH patients.
Stroke, Volume 56, Issue Suppl_1 , Page A30-A30, February 1, 2025. Background and objective:Perfusion imaging studies consistently show a substantially increased risk of hemorrhagic transformation (HT) in severely hypoperfused tissue.
Stroke, Volume 56, Issue Suppl_1 , Page ATP391-ATP391, February 1, 2025. However, inhibition of CGRP system may also lead to vasoconstriction, raising concerns about whether the long-term treatment with these antibodies in migraine patients might increase the risk of stroke or worsen outcomes if a stroke occurs while taking these medications.
Stroke: Vascular and Interventional Neurology, Ahead of Print. BACKGROUNDThrombectomy is well‐established management for acute ischemic stroke involving large vessel occlusion. The primary outcome was good functional outcome at 3 months. The odds ratio (OR) of good functional outcome at 3 months was 0.93 (95% CI, 0.68–1.28)
Stroke, Ahead of Print. The exposure was a new diagnosis of non-traumatic intracranial hemorrhage, defined as a composite of intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), and subdural hemorrhage (SDH). The outcome was a first-ever diagnosis of dementia. During a median follow up of 5.6
Stroke, Volume 56, Issue Suppl_1 , Page AWMP72-AWMP72, February 1, 2025. Introduction:Emerging technologies, such as Cone-Beam CT (CBCT), may improve workflows in acute ischemic stroke (AIS). Conclusion:CBCT had high specificity for ICH and hemorrhage types.
Stroke, Volume 56, Issue Suppl_1 , Page AWP158-AWP158, February 1, 2025. Objective:Socioeconomic disparities significantly affect the treatment and outcomes of cardiovascular and cerebrovascular diseases, including acute ischemic stroke. SES was not a significant predictor of good functional outcomes (mRS 0-2).Conclusion:This
Stroke, Volume 56, Issue Suppl_1 , Page AWP213-AWP213, February 1, 2025. Intracerebral Hemorrhagic (ICH) stroke is the second most common type of stroke and its aftermath is often more severe than ischemia. In order to improve post ICH outcome, immediate therapeutic interventions should be administered.
Stroke, Volume 56, Issue 2 , Page 527-532, February 1, 2025. BACKGROUND:Acute ischemic stroke treatment typically involves tissue-type plasminogen activator (tPA) or tenecteplase, but about 50% of patients do not achieve successful reperfusion. DNase-I, which degrades neutrophil extracellular traps, could improve thrombolytic efficacy.
Stroke, Volume 56, Issue Suppl_1 , Page AWP368-AWP368, February 1, 2025. Introduction:Oxidative stress plays an important role in both early brain injury and delayed cerebral ischemia after subarachnoid hemorrhage (SAH). In further studies, we will test how MnP-05 affects long-term outcomes of SAH. P<0.05, Fig.
Stroke, Volume 55, Issue Suppl_1 , Page AWMP81-AWMP81, February 1, 2024. Introduction:Intracerebral Hemorrhage (ICH) leads to high rates of morbidity and mortality. Malnutrition is common in stroke patients and leads to worse outcomes. 7.34) and lobar (OR 3.15, 95% CI 1.67-5.94) 5.94) groups. Albumin (OR 2.27, 95% CI 1.05-4.90)
Stroke, Volume 55, Issue Suppl_1 , Page ATP279-ATP279, February 1, 2024. Whether atrial cardiopathy is associated with the risk of intracranial hemorrhage in acute ischemic stroke (AIS) remains uncertain. Our primary outcomes included any intracranial hemorrhage (ICH) and symptomatic ICH (sICH) during follow-up.
Fully published results from Athos Therapeutics AZALEA-TIMI 71 trial for its novel Factor XI inhibitor abelacimab, confirming the drugs lower bleeding risks, but leaving researchers uncertain about its ability to prevent stroke in AFib patients. vs. 0.4%) and 4X ischemic stroke rates (csHR = 4.06). year follow-up. per 100 person-year.
Stroke, Volume 56, Issue Suppl_1 , Page AWP232-AWP232, February 1, 2025. Background:Intracerebral hemorrhage (ICH) is a critical neurological condition with high rates of mortality and morbidity. Accurate prediction of the clinical outcomes in ICH patients is essential for effective clinical management. and 47.8%, respectively.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content